Posted 4/5/2024, 10:28:52 PM
ALS Drug Relyvrio Pulled After Failing Large Trial, Maker Lays Off 70% of Staff
- ALS drug Relyvrio pulled from market after failing large clinical trial
- Relyvrio won FDA approval in 2022 despite questionable data; was required to conduct further trials
- Recent trial with 664 patients showed Relyvrio failed to meet any goals related to ALS symptoms/progression
- Maker Amylyx withdrawing drug from market, though existing patients can continue accessing it
- Amylyx laying off 70% of workforce to focus on other neurodegenerative disease drugs
